Weight Management

Study indicates that a diet high in ultra-processed food is more likely to increase the risk of colorectal cancer in men than it is women.

Dual GIP/GLP-1 agonist therapy demonstrated superior glucose control and weight loss in patients with diabetes compared to selective GLP-1 receptor agonists in preclinical and clinical trials.

Obesity, heavy alcohol consumption, and coagulopathy were some of the greatest risk factors associated with patients returning to the operating room within 48 hours of a surgery.

Very short sleep among adolescents linked to a more than 70% increased risk of obesity/overweight in children, compared to those who get optimal 8 hours.

Catherine Oakar, special assistant to the President for Public Health and Disparities in the Domestic Policy Council at The White House, discusses plans to address diet-related diseases in a conference held at The White House in September 2022.

For every 10% increase in daily intake of ultra-processed foods, people had a 25% higher risk of dementia, though the association is not proven to be causal.

Phentermine and Topiramate ER (Qsymia) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management.

A study demonstrated the role of the serotonin 1B receptor in appetite and showed that triptan, a commonly prescribed migraine medicine, may be repurposed for appetite suppression and obesity.

Liraglutide (Saxenda) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with type 2 diabetes.

Saxagliptin (Onglyza) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Study results show that there is a link between leaving the television on, night lights, and smart phones and higher disease rates.

The American Diabetes Association guidelines have self-care and lifestyle recommendations for patients and health care professionals.

Lifestyle modifications are the cornerstone of treatment.

These clear-cut guidelines help pharmacists making sure the patients are getting the right drug to set them up for success and prevent problems down the road.

The future trend in managing diabetes will extend into glycemic control, weight reduction, and renal liver, for example.

In February of this year, the new statistics came out where we're at now 37 million with diabetes and 96 million with prediabetes.

Semaglutide (Wegovy) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients.

Insurers are refusing to cover new, highly effective anti-obesity drugs, but some prescribers are getting around the issue.

Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.

Physicians often overlook those with lower BMIs who have nonalcoholic fatty liver disease and lower rates of other comorbidities, investigators say.

Clinical trial participants who took the drug lost up to 52 lb., or 24 kg, in the 72-week, phase 3 study.

Ertugliflozin (Steglatro) is a sodium glucose co-transporter 2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Psychedelic medicines like psilocybin work to re-wire the brain, potentially addressing the root cause of eating disorders rather than the symptoms.

In a clinical trial, 86.4% of patients on semaglutide achieved a 5% weight loss at week 68 compared to 31.5% with placebo.

Estosterone undecanoate (Tlando; Antares Pharma, Inc) is indicated as testosterone replacement therapy for conditions associated with a deficiency or absence of endogenous testosterone in adult patients.

Semaglutide (Ozempic; Novo Nordisk) approved as a once-weekly subcutaneous injection for the treatment of adults with type 2 diabetes.

Basaglar is indicated to improve glycemic control in adults and children with type 1 diabetes and adults with type 2 diabetes.

Empagliflozin and linagliptin (Glyxambi) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Results of studies show that women with obesity who get these weight loss procedures often also have preventative benefits.

Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.